DOCSLIB.ORG

Monthly Startups Index September 2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monthly Startups Index September 2013 Monthly Startups Index September 2013 This report sponsored by September 2013 1 MEDCITY Reports Table of Contents Readers on digital devices can click on the headings below to get directly to the page. 1 From the Editor 3 2 Digital & Health IT 4 Startups In-Depth 5 Startup Activity 13 3 Pharma and BioTech 17 Startups In-Depth 18 Startup Activity 24 4 Medical Devices & Diagnostics 26 Startups In-Depth 27 Startup Activity 33 5 Most Popular Startups This Month 36 MAIN CONTACT INFORMATION MedCity Media P.O. Box 606246 Cleveland, OH 44106 Phone: (216) 453-2662 General inquiries: [email protected] September 2013 2 MEDCITY Reports From the Editor The morning routine of the not-too-distant future Every day we write about new technology that will change healthcare. Sometimes it’s easy to see how cancer treatment or diabetes care will be different in 5 or 10 or 15 years. Other times it’s harder to see what the future will look like. The picture is still fuzzy even if you squint. From the list of startups in this month’s report, I can see a new morning routine shaped by four companies: Predictably Well, Adamant Technology, Bionym and ChartSpan Medical Technology. We will need advances in a few other areas, but these startups will drive the new way of managing your health. Veronica Combs, Editor in Chief When you wake up after a good night’s sleep thanks to Beddit, you pick up your MedCity Media phone. Your Nymi wristband unlocks it and downloads the last 12 hours of your heart- rate and blood-pressure data to your phone. You check your a five-day wellness forecast from Good Days and see that pollen counts are off the charts. You grab extra allergy meds and put them in your laptop bag, just in case. As you make your first phone call of the day, the Adamant sensor on your phone analyzes the metabolites your breath. This data too goes to your phone. All of this data goes to the personal health record on your phone that syncs with your tablet, thanks to ChartSpan’s personal health record. You have shared this record with a personal health coach. It’s the first of the month, so you get a monthly report from her: Sleep is better, cholesterol is still a little high, and you are holding steady on the total daily steps. She also reminds you of your upcoming doctor’s appointment and includes a link for sharing your PHR data with the office. This is only the home and personal side of health. These same ideas will help at hospitals and skilled nursing facilities as well. There will be even more tech advancements to improve care and saftey in those settings as well. Veronica Combs Editor MedCity News September 2013 3 MEDCITY Reports Digital & Health IT September 2013 4 MEDCITY Reports Startups In-Depth: Digital & Health IT A PHR company’s contrarian proposal: Build for the reality that interoperability may not happen By: Deanna Pogorelc Sept 5, 2013 For all of the personal health record companies out there, one called ChartSpan Medical Technologies caught my eye today. Its claim to fame is that it’s a “fully automated PHR app.” By that, the company means that users Company: can upload email files or photos of their health records to the app, and it con- ChartSpan Medical verts the contents into structured data. The app then organizes and stores a Technologies whole family’s data in the form of PHRs. CEO: But wait, you say. That’s not fully automated. A truly automated PHR would Jon-Michial Carter pull in data from the EMR systems of a person’s doctors without any efforts by the user herself. Website: Yes, responds ChartSpan co-founder and CEO Jon-Michial Carter, but it’s http://www.chartspan.com/ time to start getting real about whether that’s actually going to happen, at least any time soon. Twitter: @Arpeggi_Inc “Interoperability has been a goal for years, but it hasn’t been achieved,” Carter explained. “We all know the technology exists today to make universal interoperability happen, but if we have free access to our healthcare records as patients, a lot of people don’t make money. I just get frustrated by the disingenuous conversations about it.” He added that his team is a big fan of Blue Button, and if it became more pervasive the company would definitely work to accommodate what that technology could do. “But the truth is, 99 percent of the time we’re handed a Continued on next page September 2013 5 MEDCITY Reports Startups In-Depth: Digital & Health IT ChartSpan (Continued) piece of paper when we request our healthcare records. email from the app. We want to accommodate that process today,” he said. The ultimate goal is to be part of a paradigm shift that Carter’s young company today announced it closed a makes the patient the repository of healthcare informa- pre-seed funding round totaling just under $250,000. tion, rather than a provider, Carter stated. “Right now, a The round was led by Don Byrne, an entrepreneur in GI provider-based EHR can’t import API data from a fitness endoscopy who founded Byrne Medical (now Mediva- band or glucose reader, but a patient can,” he pointed tors), with participation from Carter and the Iron Yard out. “A provider today can’t take your human genome Digital Healthcare Accelerator, the company said. API and import it into their EHR, but a patient can. Patients can push their PHR data to anyone they want, ChartSpan’s PHR is based on proprietary optical char- but doctors can’t. We get that providers need to have acter recognition that lifts data from an image or file and that information, but who is really in a better position to converts it to digital data. But the PHR, which can be manage that data?” used on a smartphone, tablet or computer, also attach- es that original picture or record to the data it extracts. The ChartSpan PHR is set to launch in Q4 of this year. Users then can send the original record to a specialist, Until then, the Houston-based company is wrapping up or send an original copy of an immunization record to at the Iron Yard Digital Healthcare Accelerator in South a child’s nurse at school, and they can send it by fax or Carolina. September 2013 6 MEDCITY Reports Startups In-Depth: Digital & Health IT Like a meteorologist for your health, Good Days fore- casts flare-ups in autoimmune conditions By: Deanna Pogorelc Sept 11, 2013 For people with autoimmune disease, the temperature, humidity or baromet- ric pressure on any given day could mean more pain, or less pain, than the day before. Giving those people tools to prepare for what their symptoms might be has so far been a winning idea for mobile health company Predict- Company: ably Well. Predictably Well While AccuWeather and Weather.com both have tools that highlight environ- Co-Founders: mentalfactors that might play into migraine and arthritis pain, Predictably Well Juliet Monique Oberding and co-founder Juliet Oberding wanted to create something more personalized, Terje Norderhaug since each person’s disease takes a different course. Website: Oberding herself was diagnosed with rheumatoid arthritis back in 2008 and http://www.predictablywell. joined up with software developer Terje Norderhaug in 2011 to see if sensors, com/ mobile technology and predictive analytics could help predict flare-ups. The app that resulted, called Good Days, is aimed at people living with rheu- Twitter: matoid arthritis, lupus, fibromyalgia and other chronic autoimmune condi- @PredictablyWell tions. Each day, an app user selects from a set of icons to let the app know if she’s feeling good, OK or bad that day. If she wants, she can use the app’s journal- ing feature to go into more detail about her fatigue or stress levels, or where any pain is occurring. Continued on next page September 2013 7 MEDCITY Reports Startups In-Depth: Digital & Health IT Predictably well (Continued) Then the app goes to work aggregating environmental category in Qualcomm’s UPLINQ hackathon last week, data from outside sources and geographical data from according to an update on the company’s Facebook the user’s device. Using all of that, it tries to determine page. what factors contribute to a good day and to a bad day, and generates a five-day wellness forecast for that Oberding and Norderhaug are collecting early user feed- user. Like a weather forecast, it includes an icon that back to iterate in preparation for a forthcoming national indicates whether each day is expected to be good, OK launch. or bad, but also allows users to drill down into the data They’re taking the bottom-up approach to finding users that’s behind the forecast. by going straight to patients instead of through doctors Last summer, it won the popular grand choice prize at or health plans. “One of the real benefits of focusing the AT&T San Diego Apps Challenge, a contest that on patients now is you really learn to satisfy the main requires developers to use data made available by the users,” Oberding explained. “We’re working with local city. It’s currently in beta in San Diego, using ozone, people with RA and other autoimmune conditions, pollution, weather and microclimate zone data supplied reaching out to the community, interviewing them and by the city. The app also won the health and fitness connecting with them.” September 2013 8 MEDCITY Reports Startups In-Depth: Digital & Health IT App uses cognitive behavioral therapy to treat and manage eating disorders By: Stephanie Baum Sept 16, 2013 Eating disorders affect about 24 million people in the U.S.
Load more

Recommended publications
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • DDT Cover/Back April 2006.Qx
    June 2007 Vol 7 No 6 www.drugdeliverytech.com IN THIS ISSUE INTERVIEW WITH EURAND’S CHIEF COMMERCIAL OFFICER MR. JOHN FRAHER The eFlow® Nebulizer 30 Shabtai Bauer, PhD Markus Tservistas, PhD Bioadhesive Microspheres 54 Jayvadan Patel, PhD Transdermal Solutions 68 Gary W. Cleary, PhD FEATURING Imaging CROs 72 Richard Taranto Autoimmune The science & business of specialty pharma, biotechnology, and drug delivery Diseases 80 Douglas Kerr, MD Adam Kaplin, MD JuliaJulia Rashba-Rashba- Shaukat Ali, Richard Step,Step, PhDPhD PhD Sitz, MBA EfEfficientficient PulmonaryPulmonary HMW Povidone Beyond Sticky Partnering With DeliveryDelivery ofof BiologicalBiological PolymerPolymer-Based-Based toto Sophisticated:Sophisticated: NovaQuest 84 MoleculesMolecules asas Films for The Many PROMAXXPROMAXX Fast-Dissolving Dimensions Ms. Cindy H. Dubin MicrMicrospheresospheres Drug Delivery of Adhesives June 2007 Vol 7 No 6 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel:
    [Show full text]
  • Drug Delivery Technology
    * DDT Nov-Dec 2006 Round 5 11/10/06 7:20 PM Page 2 November/December 2006 Vol 6 No 10 IN THIS ISSUE Corporate Profiles 16 Drug Delivery Technologies 73 Excipients, Polymers, Liposomes & Lipids 90 Contract Pharmaceutical & Biological Development Services 96 Machinery & Laboratory Equipment and Software 109 Technology Spotlight 114 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 3 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 4 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 5 November/December 2006 Vol 6 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] International Ralph Vitaro 219 Changebridge Road Vol 6 No 10 Montville, NJ 07045 Tel: (973) 299-1200 Fax: (973) 299-7937 E-mail: [email protected] Mailing List Rental Candy Brecht Tel: (703) 706-0383 Fax: (703) 549-6057 E-mail: [email protected] All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety November/December 2006 of artwork, photographs, or manuscripts.
    [Show full text]
  • Happy-Healthy-Hormones-Latest.Pdf
    HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE HAPPY HEALTHY HORMONES Daved Rosensweet M.D. HOW TO THRIVE IN MENOPAUSE This book has been written and published to provide information and should not be used as a substitute for the recommendations of your health care professional. Be- cause each person and medical situation are unique, the reader is urged to review this information with a qualified health professional. You should not consider the infor- mation contained in this text to represent the practice of medicine or to replace consultation with a physician or other qualifiedhealth care provider. The Menopause Method, Inc. Sarasota, Florida 941-366-3768 www.menopausemethod.com [email protected] The Menopause Method: A Woman’s Guide to Navigating Menopause, sixth edition, 2017. Copyright © 2001, 2002, 2006, 2007, 2014, 2017 by Daved Rosensweet M.D. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photo- copying, recording, or otherwise, without the prior written permission of the copyright owner. Sixth Edition 2017 ISBN: 9780999744901 Published in the United States of America Dedication This book is dedicated, first and foremost, to my patients in menopause: for 24 years, woman by woman, moment by moment, molecule by molecule, you have given me what has culminated in these pages. You know who you are, and I do thank you. Writing this dedication has turned out to be a deep and heartfelt experience for me.
    [Show full text]
  • M1 Covered Drug List
    Metallic M1 - List of Covered Drugs (Formulary) Effective Date: 09-01-2021 The Metallic M1 Formulary is used by these plans: Plus HSA Qualified Bronze 5950 Plus HSA Qualified Gold 1500 Plus HSA Qualified Silver 2800 Plus HSA Qualified Silver 3500 Plus HSA Qualified Bronze 6900 What is the list of covered drugs (Formulary)? This document contains a list of generic, brand and specialty drugs covered under your plan. How is the list of covered drugs developed? The drug list is developed with an independent committee of physicians, pharmacists and other healthcare providers called the Pharmacy and Therapeutics Committee. This independent committee reviews and selects drugs for coverage based on each drugs safety, effectiveness and cost. The committee meets at least quarterly to review new drugs to market to determine placement on this list and also reviews updated safety, effectiveness and cost information for existing drugs to ensure the formulary remains up to date with current medical evidence. How do I use the Formulary? Drugs are listed by categories depending on the type of medical conditions that they are used to treat. If you know what your drug is used for, look for the category name in the list that begins below. Then look under the category name for your drug. If you are not sure what category to look under, you can also search for the drug in the Index. The Index provides an alphabetical list of all of the drugs included in this document. Next to the name of the drug in the Index, you will see the page number where you can find coverage information.
    [Show full text]
  • A Review on Transdermal Spray
    Review Article Mathews Journal of Pharmaceutical Science A Review on Transdermal Spray: Formulation Aspect Uttam Kumar Mandal1, Bappaditya Chatterjee1, Fatin Husna Binti Pauzi1 1Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Malaysia. Corresponding Author: Uttam Kumar Mandal, Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Bander Indera Mahkota, Kuantan 25200, Pahang, Malaysia. Tel: +6 0109062750; Email: [email protected] Received Date: 22 Feb 2016 Copyright © 2016 Mandal UK Accepted Date: 24 Mar 2016 Citation: Mandal UK (2016) A Review on Transdermal Spray: Published Date: 30 Mar 2016 Formulation Aspect. M J Pharma 1(1): 006. ABSTRACT Transdermal spray offers numerous advantages over the other conventional transdermal drug delivery forms such as gel, ointment and patches, in terms of its cosmeceutical appearance, ready availability for application, flexibility in dosage design, less occurrence of skin irritation and faster drying rate from the application site due to the use of volatile solvent. However, compared to other transdermal drug delivery dosage forms, transdermal spray has the least and limited num- ber of products approved for marketing. Among the drugs are, Evamist®, an estradiol formulation approved in 2007 by the FDA followed by Axiron® a non-spray solution to treat low testosterone in men and Recuvyra®, a pain reliever solution indicated for dogs. This review article focuses current status on the formulation and evaluation of transdermal spray in the background of the role and effects of its composition specially the selection of drugs, volatile solvents, penetration enhancers and film forming polymer, etc. The limitation of transdermal spray highlighted in this review is the concern of its use, especially, the third party exposure particularly for endocrinology indication.
    [Show full text]
  • Preparation and the Biopharmaceutical Evaluation for the Metered Dose Transdermal Spray of Dexketoprofen
    Hindawi Publishing Corporation Journal of Drug Delivery Volume 2014, Article ID 697434, 12 pages http://dx.doi.org/10.1155/2014/697434 Research Article Preparation and the Biopharmaceutical Evaluation for the Metered Dose Transdermal Spray of Dexketoprofen Wangding Lu, Huafei Luo, Zhuangzhi Zhu, Yubo Wu, Jing Luo, and Hao Wang National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China Correspondence should be addressed to Hao Wang; [email protected] Received 9 October 2013; Revised 22 November 2013; Accepted 26 November 2013; Published 11 February 2014 Academic Editor: Sri Rama K Yellela Copyright © 2014 Wangding Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The objective of the present work was to develop a metered dose transdermal spray (MDTS) formulation for transdermal delivery of dexketoprofen (DE). DE release from a series of formulations was assessed in vitro. Various qualitative and quantitative parameters like spray pattern, pump seal efficiency test, average weight per metered dose, and dose uniformity were evaluated. The optimized formulation with good skin permeation and an appropriate drug concentration and permeation enhancer (PE) content was developed incorporating 7% (w/w, %) DE, 7% (v/v, %) isopropyl myristate (IPM), and 93% (v/v, %) ethanol. In vivo pharmacokinetic study indicated that the optimized formulation showed a more sustainable plasma-concentration profile compared with the Fenli group. The antiinflammatory effect of DE MDTS was evaluated by experiments involving egg-albumin-induced paw edema inrats and xylene-induced ear swelling in mice.
    [Show full text]
  • Transdermal Spray in Hormone Delivery
    Yapar & Inal2 Tropical Journal of Pharmaceutical Research March 2014; 13 (3): 469-474 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v13i3.23 Review Article Transdermal Spray in Hormone Delivery Evren Algın-Yapar1* and Özge İnal2 1The Ministry of Health of Turkey, Turkish Medicines and Medical Devices Agency, Söğütözü Mahallesi, 2176. Sokak No. 5, 06520 Çankaya-Ankara, 2Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Ankara, 06100 Tandoğan- Ankara, Turkey *For correspondence: Email: [email protected], [email protected]; Tel: +90 0532 382 56 86 Received: 23 July 2012 Revised accepted: 15 February 2014 Abstract This review examines advances in hormone delivery, particularly using transdermal spray. Transdermal gels, emulsions, patches, subcutaneous implants and sprays have been developed for transdermal hormone therapy in recent years. Transdermal sprays, in their general form of metered-dose transdermal spray, possess major advantages such as enhanced passive transdermal drug delivery with little or no skin irritations, improved cosmetic acceptability, dose flexibility, uniform distribution on the application site and ease of manufacture, and have thus assumed significant importance in hormone delivery. Estradiol, nestrone, testosterone and hydrocortisone aceponate are some of the drugs prepared as metered-dose
    [Show full text]
  • FEP® Blue Focus Formulary (907)
    FEP® Blue Focus Formulary (907) Effective January 1, 2022 The FEP formulary includes a preferred drug list which is comprised of Tier 1, generics and Tier 2, preferred brand-name drugs, preferred generic specialty drugs, and preferred brand-name specialty drugs. Ask your physician if there is a generic drug available to treat your condition. If there is no generic drug available, ask your physician to prescribe a preferred brand-name drug. The preferred brand-name drugs within our formulary are listed to identify medicines that are clinically appropriate and cost-effective. Click on the category name in the Table of Contents below to go directly to that page INTRODUCTION ........................................................................................................................................................................................................................ 5 PREFACE ................................................................................................................................................................................................................................... 5 PRIOR APPROVAL ................................................................................................................................................................................................................... 5 QUANTITY LIMITATIONS ........................................................................................................................................................................................................
    [Show full text]
  • Topical and Transdermal Drug Products
    STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies Pharmacopeial Forum 750 of the USPC or the USP Council of Experts Vol. 35(3) [May–June 2009] Topical and Transdermal Drug Products The Topical/Transdermal Ad Hoc Advisory Panel for the USP Performance Tests of Topical and Transdermal Dosage Forms: Clarence T. Ueda (Chair), Vinod P. Shah (USP Scientific Liaison), Kris Derdzinski, Gary Ewing, Gordon Flynn, Howard Maibach, Margareth Marques (USP Scientific Liaison),a Howard Rytting,b Steve Shaw, Kailas Thakker, and Avi Yacobi. ABSTRACT This Stimuli article provides general information about the test methods that should be employed to ensure the quality and performance of topical and transdermal drug products. The term topical drug products refers to all formulations applied to the skin except transdermal delivery systems (TDS) or transdermal patches that will be addressed separately. INTRODUCTION Therefore, the in vitro release test for those products also may differ significantly and may require different Drug products topically administered via the skin fall types of apparatus. At present, a product performance into two general categories, those applied for local action test exists only for semisolid formulations, specifically and those for systemic effects. Local actions include creams, ointments, and gels. That test employs the ver- those at or on the surface of the skin, those that exert tical diffusion cell (VDC) system. The VDC system is sim- their actions on the stratum corneum, and those that ple to operate and yields reliable and reproducible results modulate the function of the epidermis and/or the der- when employed by properly trained laboratory person- mis.
    [Show full text]
  • Time for Change in Medicines, 100 Testimonials on Physical Chemistry Relief Curing!
    Time for change in Medicines, 100 testimonials on Physical Chemistry Relief Curing! Testimonial #0 Chiquita: Skin Clearing, Psoriasis Two years ago one of my best friends was trying to get pregnant. Her and her husband had been trying for about 6 months when he came down with a severe break out of psoriasis. They were unable to get rid of it. I had been given a sample of "Pico Skin Relief" to try and had not used any. I thought what we had to loose. So I gave it to them to try. He suds up and sat in the shower for 30 mins before rising off. He then applied a thin coating on just the worst spots. He used it every day like this for 2 weeks. Honest to goodness the next day the psoriasis started fading. Within 2 weeks his skin was soft and no longer red and swollen. They now are proud parents of a baby boy. This soap is a miracle. He has not had another break out since. Thank you so much. Chiquita Testimonial #1 Jeanine: Skin Clearing, Heal Painful Lesions, Now I Have Soft Skin, Pulls Out Sub-Dermal Debris This "Pico Skin Relief" has become a valuable asset in my skin clearing efforts. It helps heal painful lesions. This 1st couple of days I used it I had a new rash that itched and was cleared in 2 days. The "Pico Skin Relief" leaves the skin soft and does not dry it out as some other helps do. Also, it seems to pull out sub-dermal debris like the black dots.
    [Show full text]
  • Preparation and the Biopharmaceutical Evaluation for the Metered Dose Transdermal Spray of Dexketoprofen
    Hindawi Publishing Corporation Journal of Drug Delivery Volume 2014, Article ID 697434, 12 pages http://dx.doi.org/10.1155/2014/697434 Research Article Preparation and the Biopharmaceutical Evaluation for the Metered Dose Transdermal Spray of Dexketoprofen Wangding Lu, Huafei Luo, Zhuangzhi Zhu, Yubo Wu, Jing Luo, and Hao Wang National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China Correspondence should be addressed to Hao Wang; [email protected] Received 9 October 2013; Revised 22 November 2013; Accepted 26 November 2013; Published 11 February 2014 Academic Editor: Sri Rama K Yellela Copyright © 2014 Wangding Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The objective of the present work was to develop a metered dose transdermal spray (MDTS) formulation for transdermal delivery of dexketoprofen (DE). DE release from a series of formulations was assessed in vitro. Various qualitative and quantitative parameters like spray pattern, pump seal efficiency test, average weight per metered dose, and dose uniformity were evaluated. The optimized formulation with good skin permeation and an appropriate drug concentration and permeation enhancer (PE) content was developed incorporating 7% (w/w, %) DE, 7% (v/v, %) isopropyl myristate (IPM), and 93% (v/v, %) ethanol. In vivo pharmacokinetic study indicated that the optimized formulation showed a more sustainable plasma-concentration profile compared with the Fenli group. The antiinflammatory effect of DE MDTS was evaluated by experiments involving egg-albumin-induced paw edema inrats and xylene-induced ear swelling in mice.
    [Show full text]